These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27585582)

  • 1. Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study.
    Wilding J; Bailey C; Rigney U; Blak B; Beekman W; Emmas C
    Diabetes Ther; 2016 Dec; 7(4):695-711. PubMed ID: 27585582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.
    Scheerer MF; Rist R; Proske O; Meng A; Kostev K
    Diabetes Metab Syndr Obes; 2016; 9():337-345. PubMed ID: 27822077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme.
    Gordon J; Danne T; Beresford-Hulme L; Bennet H; Tank A; Edmonds C; Thorén F; Scheerer MF; McEwan P
    Diabetes Ther; 2020 May; 11(5):1135-1146. PubMed ID: 32274678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Dapagliflozin as Add-On to Metformin with or without Other Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus: A Multicentre, Retrospective, Real-World Database Study.
    Sethi B; Sahay R; Tiwaskar M; Negalur V; Dhediya R; Gaurav K; Rathod R; Kotak B; Dhanaki G; Shah S
    Drugs Real World Outcomes; 2024 Mar; 11(1):81-90. PubMed ID: 37898577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia.
    Alsafwani DM; Alotaibi HN; Alzaid JA; Alghamdi A; Almakhaita HM
    Cureus; 2022 Mar; 14(3):e23554. PubMed ID: 35371841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Outcomes of Dapagliflozin Use in Real-Life Clinical Settings in Endocrinology Clinics of Islamabad, Pakistan.
    Kamin M; Ishtiaq O; Raashid K; Wahab MU; Khan SA; Raja U
    Cureus; 2020 Jun; 12(6):e8565. PubMed ID: 32550088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study.
    Pallarés-Carratalá V; Ruiz-García A; Serrano-Cumplido A; Fragoso AS; Fernández-Pascual V; Sánchez-Sánchez B; Cervera-Pérez MI; Alonso-Moreno FJ; Arranz-Martínez E; Barquilla-García A; Rey-Aldana D; García JP; Cinza-Sanjurjo S;
    Clin Investig Arterioscler; 2024 Jun; ():. PubMed ID: 38910079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.
    Sosale B; Sosale A; Bhattacharyya A
    Diabetes Ther; 2016 Dec; 7(4):765-776. PubMed ID: 27761881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis.
    Fadini GP; Morales C; Caballero I; González B; Tentolouris N; Consoli A
    Diabetes Metab Syndr Obes; 2022; 15():3533-3541. PubMed ID: 36411790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin: an effective adjunctive treatment in type 1 diabetes.
    Yadegarfar G; Livingston M; Cortes G; Alshames R; Leivesley K; Metters A; Horne L; Steele T; Heald AH
    Cardiovasc Endocrinol Metab; 2021 Jun; 10(2):132-136. PubMed ID: 34124604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
    Braha A; Albai A; Timar R; Diaconu L; Vasiluță L; Cipu D; Timar B; Sima A
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA.
    Blonde L; Meneghini L; Peng XV; Boss A; Rhee K; Shaunik A; Kumar S; Balodi S; Brulle-Wohlhueter C; McCrimmon RJ
    Diabetes Ther; 2018 Jun; 9(3):1347-1358. PubMed ID: 29600507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients.
    Wang DD; Zhang C; Hu K; He SM; Zhu P; Chen X
    Front Pharmacol; 2022; 13():972878. PubMed ID: 36686651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study.
    Morales C; Merino-Torres JF; Moreno-Moreno P; Lainez M; Tejado I; Yoldi A; Gutiérrez Medina S; Soto A; Botana MA; Bellido V; Caballero I
    Drugs Context; 2022; 11():. PubMed ID: 35251200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study.
    Gordon J; McEwan P; Idris I; Evans M; Puelles J
    BMJ Open Diabetes Res Care; 2018; 6(1):e000512. PubMed ID: 29755756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.
    Liu J; Chang X; Ding X; He X; Wang J; Wang G
    Diabetol Metab Syndr; 2023 Dec; 15(1):251. PubMed ID: 38044448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK.
    Bennett H; McEwan P; Bergenheim K; Gordon J
    Diabetes Ther; 2014 Dec; 5(2):567-78. PubMed ID: 25185770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Cycling on Glycaemia, Blood Pressure, and Weight in Young Individuals with Type 2 Diabetes.
    Jhingan A; Jhingan RM
    J Clin Diagn Res; 2017 Jul; 11(7):OC09-OC11. PubMed ID: 28892953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.